Antifungal Activity againstCandidaSpecies of the Selective Serotonin‐Reuptake Inhibitor, Sertraline | Zendy

Cornelia LassFlörl | Zendy; Manfred P. Dierich | Zendy; Dietmar Fuchs | Zendy; Elisabeth I. Semenitz | Zendy; Maximilian Ledochowski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antifungal Activity againstCandidaSpecies of the Selective Serotonin‐Reuptake Inhibitor, Sertraline

Author(s) -

Cornelia LassFlörl,

Manfred P. Dierich,

Dietmar Fuchs,

Elisabeth I. Semenitz,

Maximilian Ledochowski

Publication year - 2001

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/324589

Subject(s) - sertraline , serotonin reuptake inhibitor , medicine , reuptake inhibitor , antifungal , serotonin , pharmacology , antidepressant , dermatology , receptor , hippocampus

Three patients with premenstrual dysphoric disorder (PMDD) and recurrent vulvovaginal candidiasis (VVC) underwent sertraline therapy (Tresleen, a selective serotonin-reuptake inhibitor; Pfizer) for PMDD. During sertraline intervention, patients had no recurrent episodes of acute VVC. Antifungal activity was observed for sertraline against various isolates of Candida species.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research